Patents by Inventor Pauline Contamin
Pauline Contamin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10987309Abstract: The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.Type: GrantFiled: December 6, 2012Date of Patent: April 27, 2021Assignee: ETHYPHARMInventors: Catherine Herry, Pauline Contamin
-
Publication number: 20170016925Abstract: A pharmaceutical form for combating chemical submission includes an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced. The compound is selected from the group consisting of an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Applicant: ETHYPHARMInventors: CATHERINE HERRY, PAULINE CONTAMIN, EMMANUEL DUPAU
-
Publication number: 20160361262Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: ApplicationFiled: April 7, 2016Publication date: December 15, 2016Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Publication number: 20160310434Abstract: The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.Type: ApplicationFiled: December 18, 2014Publication date: October 27, 2016Applicant: ETHYPHARMInventors: CATHERINE HERRY, PAULINE CONTAMIN
-
Patent number: 9439866Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.Type: GrantFiled: September 28, 2010Date of Patent: September 13, 2016Assignee: Angelini Pharma, Inc.Inventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia Soulhi
-
Publication number: 20150306041Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: ApplicationFiled: February 23, 2015Publication date: October 29, 2015Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Patent number: 8962019Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: GrantFiled: October 15, 2010Date of Patent: February 24, 2015Assignee: Angelini Pharma, Inc.Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Publication number: 20140322321Abstract: The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.Type: ApplicationFiled: December 6, 2012Publication date: October 30, 2014Applicant: ETHYPHARMInventors: Catherine Herry, Pauline Contamin
-
Patent number: 8795723Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: GrantFiled: September 11, 2006Date of Patent: August 5, 2014Assignee: Angelini Pharma Inc.Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Publication number: 20130108556Abstract: The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.Type: ApplicationFiled: July 5, 2011Publication date: May 2, 2013Applicant: EthypharmInventors: Catherine Herry, Pauline Contamin, Emmanuel Dupau
-
Publication number: 20130098286Abstract: The present invention relates to a method for combating chemical submission, which comprises: putting into solution, in a beverage, a pharmaceutical form comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, even more preferentially from 0.3 to 2 mg of at least one water-soluble colouring agent chosen from: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarine green SS, orange II, tartrazine and Sunset yellow FCF, detecting the pharmaceutical form, said detection being characterized by the immediate change in colour of the beverage; it also relates to the use of said colorant for combating chemical submission, and also to a non-film-coated solid pharmaceutical form comprising said colorant.Type: ApplicationFiled: July 5, 2011Publication date: April 25, 2013Inventors: Catherine Herry, Pauline Contamin, Emmanuel Dupau
-
Patent number: 8414919Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: GrantFiled: October 15, 2010Date of Patent: April 9, 2013Assignee: Angelini Labopharm, LLCInventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Publication number: 20110033537Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: ApplicationFiled: October 15, 2010Publication date: February 10, 2011Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Publication number: 20110027370Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: ApplicationFiled: October 15, 2010Publication date: February 3, 2011Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Publication number: 20110021535Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.Type: ApplicationFiled: September 28, 2010Publication date: January 27, 2011Inventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia Soulhi
-
Publication number: 20110015205Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.Type: ApplicationFiled: September 28, 2010Publication date: January 20, 2011Inventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia Soulhi
-
Patent number: 7829120Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.Type: GrantFiled: September 11, 2006Date of Patent: November 9, 2010Assignees: Labopharm Inc., Labopharm Europe Limited, Labopharm (Barbados) LimitedInventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia Soulhi
-
Publication number: 20070128269Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: ApplicationFiled: September 11, 2006Publication date: June 7, 2007Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Ma
-
Publication number: 20070128275Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.Type: ApplicationFiled: September 11, 2006Publication date: June 7, 2007Inventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Ma, Angela Ferrada, Fouzia Soulhi